Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 2:05 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 200 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: "uveal melanoma" Condition: Melanoma Clear all
Completed No phase listed Observational

Study of Tumor Samples in Patients Undergoing Radiation Therapy or Surgery For Primary Melanoma of the Eye

NCT00952939
View directory record Official record
Conditions
Intraocular Melanoma
Interventions
fluorescence in situ hybridization, laboratory biomarker analysis, fine-needle aspiration, therapeutic conventional surgery, Questionnaires
Genetic · Other · Procedure
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 29, 2015 · Synced Jul 23, 2026, 2:05 PM EDT
Completed Phase 1 Interventional

Ranibizumab in Combination With Proton Beam Irradiation for Choroidal Melanoma

NCT00765921
View directory record Official record
Conditions
Choroidal Melanoma
Interventions
ranibizumab
Drug
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 1, 2016 · Synced Jul 23, 2026, 2:05 PM EDT
Completed Phase 1 Interventional

Targeted Imaging of Melanoma for Alpha-Particle Radiotherapy

NCT04904120
View directory record Official record
Conditions
Melanoma (Skin), Melanoma Stage IV, Melanoma, Uveal, Melanoma, Mucosal
Interventions
[203Pb]VMT01, [68Ga]VMT02
Drug
Lead sponsor
Perspective Therapeutics
Industry
Eligibility
18 Years to 89 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 6, 2023 · Synced Jul 23, 2026, 2:05 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study in Subjects With Small Primary Choroidal Melanoma

NCT03052127
View directory record Official record
Conditions
Uveal Melanoma, Ocular Melanoma, Choroidal Melanoma
Interventions
Light-activated AU-011, Laser Activation
Drug · Device
Lead sponsor
Aura Biosciences
Industry
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
13
States / cities
Tucson, Arizona • Los Angeles, California • Palo Alto, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2024 · Synced Jul 23, 2026, 2:05 PM EDT
Completed Phase 2 Interventional Results available

A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001)

NCT03207347
View directory record Official record
Conditions
Mesothelioma, Uveal Melanoma, Renal Cell Carcinoma, Cholangiocarcinoma
Interventions
Niraparib
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 80 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
3
States / cities
Gainesville, Florida • Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Sep 14, 2023 · Synced Jul 23, 2026, 2:05 PM EDT
Terminated Phase 1 Interventional

Stereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-200M for the Treatment of Melanoma Brain Metastases

NCT05341349
View directory record Official record
Conditions
Clinical Stage IV Cutaneous Melanoma AJCC v8, Melanoma of Unknown Primary, Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma, Metastatic Mucosal Melanoma, Metastatic Ocular Melanoma, Pathologic Stage IV Cutaneous Melanoma AJCC v8
Interventions
Ipilimumab, Nivolumab, Pembrolizumab, Stereotactic Radiosurgery, Tumor Treating Fields Therapy
Biological · Radiation · Procedure
Lead sponsor
Emory University
Other
Eligibility
22 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Jul 23, 2026, 2:05 PM EDT
Terminated Early Phase 1 Interventional

Radioembolization and Ipilimumab in Treating Patients With Uveal Melanoma With Liver Metastases

NCT01730157
View directory record Official record
Conditions
Ciliary Body and Choroid Melanoma, Medium/Large Size, Ciliary Body and Choroid Melanoma, Small Size, Extraocular Extension Melanoma, Iris Melanoma, Liver Metastases, Metastatic Intraocular Melanoma, Recurrent Intraocular Melanoma, Stage IV Intraocular Melanoma
Interventions
ipilimumab, yttrium Y 90 glass microspheres, laboratory biomarker analysis
Biological · Radiation · Other
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 9, 2016 · Synced Jul 23, 2026, 2:05 PM EDT
Completed Phase 2 Interventional

Temozolomide and Interferon Alfa in Treating Patients With Stage III or Stage IV Melanoma

NCT00027742
View directory record Official record
Conditions
Intraocular Melanoma, Melanoma (Skin)
Interventions
pegylated interferon alfa, temozolomide
Biological · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 4, 2013 · Synced Jul 23, 2026, 2:05 PM EDT
Completed Phase 1 Interventional

Study of Immunotherapy Plus ADI-PEG 20 for the Treatment of Advanced Uveal Melanoma

NCT03922880
View directory record Official record
Conditions
Uveal Melanoma
Interventions
ADI PEG20, Nivolumab, Ipilimumab
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 14, 2025 · Synced Jul 23, 2026, 2:05 PM EDT
Recruiting Phase 3 Interventional

Neoadjuvant Darovasertib in Primary Uveal Melanoma

NCT07015190
View directory record Official record
Conditions
Uveal Melanoma
Interventions
Darovasertib, Primary Local Therapy
Drug · Procedure
Lead sponsor
IDEAYA Biosciences
Industry
Eligibility
18 Years and older
Enrollment
520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
35
States / cities
Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Jul 23, 2026, 2:05 PM EDT
Completed Phase 3 Interventional

Percutaneous Hepatic Perfusion in Patients With Hepatic-dominant Ocular Melanoma

NCT02678572
View directory record Official record
Conditions
Melanoma, Ocular
Interventions
Melphalan/HDS
Combination Product
Lead sponsor
Delcath Systems Inc.
Industry
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
10
States / cities
Tucson, Arizona • Palo Alto, California • Tampa, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2023 · Synced Jul 23, 2026, 2:05 PM EDT
Completed Phase 1 Interventional

A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas

NCT04551352
View directory record Official record
Conditions
Cutaneous Melanoma, Uveal Melanoma, Mucosal Melanoma
Interventions
RO7293583, Tocilizumab, Obinutuzumab, Adalimumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
4
States / cities
Boston, Massachusetts • New York, New York • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2022 · Synced Jul 23, 2026, 2:05 PM EDT
Terminated Phase 1 Interventional

A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors

NCT05576077
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer, Uveal Melanoma, Cutaneous Melanoma, Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma
Interventions
TBio-4101, Pembrolizumab
Biological · Drug
Lead sponsor
Turnstone Biologics, Corp.
Industry
Eligibility
18 Years to 70 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
11
States / cities
Irvine, California • Hollywood, Florida • Miami, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2025 · Synced Jul 23, 2026, 2:05 PM EDT
Active, not recruiting No phase listed Observational

A Registry of Subjects With Primary Indeterminate Lesions or Choroidal Melanoma

NCT03941379
View directory record Official record
Conditions
Choroidal Melanoma, Indeterminate Lesions of Eye
Interventions
Not listed
Lead sponsor
Aura Biosciences
Industry
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
16
States / cities
Tucson, Arizona • Los Angeles, California • Palo Alto, California + 13 more
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Jul 23, 2026, 2:05 PM EDT
Recruiting Phase 1 Interventional

A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.

NCT06022029
View directory record Official record
Conditions
Triple Negative Breast Cancer, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Lymphoma, Non-Hodgkin, Mantle Cell Lymphoma, Bladder Cancer, Uveal Melanoma, Recurrent, Cervix Cancer, Carcinoma in Situ, Head and Neck Squamous Cell Carcinoma, Skin Cancer, Metastatic Cancer, Tumor, Solid, Tumor Recurrence
Interventions
ONM-501, Cemiplimab
Drug
Lead sponsor
OncoNano Medicine, Inc.
Industry
Eligibility
18 Years and older
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
9
States / cities
Los Angeles, California • Tamarac, Florida • Canton, Ohio + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Jul 23, 2026, 2:05 PM EDT
Recruiting Phase 1 Interventional

A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit

NCT06805825
View directory record Official record
Conditions
Gastrointestinal Stromal Tumors, Small-cell Lung Cancer, Adenoid Cystic Carcinoma, Uveal Melanoma, Neuroendocrine Tumors, Chromophobe Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma
Interventions
NN3201
Drug
Lead sponsor
Novelty Nobility, Inc.
Industry
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
5
States / cities
Ann Arbor, Michigan • Cleveland, Ohio • Portland, Oregon + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2025 · Synced Jul 23, 2026, 2:05 PM EDT
Completed Phase 1 Interventional

Single Arm Trial of Tumor-Treating Fields in Combination With Nivolumab and Ipilimumab in Metastatic Uveal Melanoma

NCT05004025
View directory record Official record
Conditions
Uveal Melanoma
Interventions
Novocure Optune, Opdivo, Yervoy
Device · Drug
Lead sponsor
HonorHealth Research Institute
Other
Eligibility
18 Years to 100 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
2
States / cities
Scottsdale, Arizona • Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 14, 2025 · Synced Jul 23, 2026, 2:05 PM EDT
Completed Phase 1 Interventional

Vaccine Therapy in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

NCT00471471
View directory record Official record
Conditions
Intraocular Melanoma, Malignant Conjunctival Neoplasm, Melanoma (Skin)
Interventions
Peptide vaccine, GM-CSF, PF3512676
Biological
Lead sponsor
Ahmad Tarhini
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 21, 2017 · Synced Jul 23, 2026, 2:05 PM EDT
Completed Phase 1 Interventional

Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma

NCT05628883
View directory record Official record
Conditions
Metastatic Melanoma, Unresectable Melanoma, Acral Melanoma, Mucosal Melanoma, Cutaneous Melanoma, Ocular Melanoma, Uveal Melanoma, Iris Melanoma, Conjunctival Melanoma, Non-Cutaneous Melanoma
Interventions
TBio-4101, Cyclophosphamide, Fludarabine, Interleukin-2
Biological · Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Jul 23, 2026, 2:05 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Marqibo in Metastatic Malignant Uveal Melanoma

NCT00506142
View directory record Official record
Conditions
Metastatic Malignant Uveal Melanoma
Interventions
Marqibo® (vincristine sulfate liposomes injection)
Drug
Lead sponsor
Spectrum Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
4
States / cities
Los Angeles, California • Denver, Colorado • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2019 · Synced Jul 23, 2026, 2:05 PM EDT
Completed No phase listed Observational

Long Term Results of Combined Transpupillary Thermotherapy (TTT) Indocyanine Green (ICG) Based Photodynamic Therapy (PDT) in Choroidal Melanoma

NCT01253759
View directory record Official record
Conditions
Choroidal Melanoma
Interventions
TTT + ICG-based PDT
Procedure
Lead sponsor
New England Retina Associates
Other
Eligibility
18 Years to 95 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Hamden, Connecticut
Source: ClinicalTrials.gov public record
Updated May 2, 2013 · Synced Jul 23, 2026, 2:05 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

NCT04198766
View directory record Official record
Conditions
Solid Tumor, Non-Small Cell Lung Cancer, Head and Neck Cancer, Melanoma, Gastric Cancer, Renal Cell Carcinoma, Urothelial Carcinoma
Interventions
INBRX-106 - Hexavalent OX40 agonist antibody, pembrolizumab 200 mg, pembrolizumab 400 mg, Carboplatin AUC-5, Carboplatin AUC-6, Pemetrexed 500 mg/m2, Cisplatin 75mg/m2, Paclitaxel 200mg/m2, Nab paclitaxel 100mg/m2
Drug
Lead sponsor
Inhibrx Biosciences, Inc
Industry
Eligibility
18 Years and older
Enrollment
296 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
30
States / cities
Duarte, California • Glendale, California • Los Angeles, California + 25 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Jul 23, 2026, 2:05 PM EDT
Completed Phase 2 Interventional Results available

Sorafenib, Carboplatin, and Paclitaxel in Treating Patients With Stage IV Melanoma of the Eye

NCT00329641
View directory record Official record
Conditions
Ciliary Body and Choroid Melanoma, Medium/Large Size, Extraocular Extension Melanoma, Iris Melanoma, Metastatic Intraocular Melanoma, Recurrent Intraocular Melanoma
Interventions
carboplatin, paclitaxel, sorafenib tosylate
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 30, 2014 · Synced Jul 23, 2026, 2:05 PM EDT
Completed Phase 2 Interventional

Pyrazoloacridine in Treating Patients With Metastatic Skin or Eye Melanoma

NCT00003802
View directory record Official record
Conditions
Intraocular Melanoma, Melanoma (Skin)
Interventions
pyrazoloacridine
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2002
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 16, 2012 · Synced Jul 23, 2026, 2:05 PM EDT